Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Saad Z Usmani; Alfred L Garfall; Amrita Krishnan

doi:10.1016/s0140-6736(21)01338-6

doi.org/10.1016/s0140-6736(21)01338-6

Clinical trial paper

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Saad Z Usmani,Alfred L Garfall,Amrita Krishnan

The Lancet88.50

Volume: 398, Issue: 10301, Pages: 665 - 674

Published: Aug 1, 2021

Paper Fields

Paper Details

Title

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

DOI

doi.org/10.1016/s0140-6736(21)01338-6

Published Date

Aug 1, 2021

Journal

The Lancet

Volume

398

Issue

10301

Pages

665 - 674

Notes

History